NASDAQ
REXN

Rexahn Pharmaceuticals, Inc

Prices are adjusted according to historical splits.

Rexahn Pharmaceuticals, Inc Stock Price

Vitals

Today's Low:
$
Today's High:
$
Open Price:
$
52W Low:
$1.2626
52W High:
$4.26
Prev. Close:
$
Volume:

Company Statistics

Market Cap.:
$0.009 billion
Book Value:
2.925
Revenue TTM:
$0.001 billion
Operating Margin TTM:
-626.1%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-32.23%
Return on Equity TTM:
-67.16%

Company Profile

Rexahn Pharmaceuticals, Inc had its IPO on 2005-05-23 under the ticker symbol REXN.

The company operates in the sector and industry. Rexahn Pharmaceuticals, Inc has a staff strength of 5 employees.

Stock update

Shares of Rexahn Pharmaceuticals, Inc opened at $0 at the start of the last trading session i.e. .

The stocks traded within a range of $0 - $0, and closed at $0.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Rexahn Pharmaceuticals, Inc have increased by 0%.

Rexahn Pharmaceuticals, Inc's Key Ratios

Rexahn Pharmaceuticals, Inc has a market cap of $0.009 billion, indicating a price to book ratio of 1.2966 and a price to sales ratio of 7.0794.

In the last 12-months Rexahn Pharmaceuticals, Inc’s revenue was $0.001 billion with a gross profit of $0.000 billion and an EBITDA of $-0.017 billion. The EBITDA ratio measures Rexahn Pharmaceuticals, Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Rexahn Pharmaceuticals, Inc’s operating margin was -626.1% while its return on assets stood at -32.23% with a return of equity of -67.16%.

In Q2, Rexahn Pharmaceuticals, Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Rexahn Pharmaceuticals, Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
None

Its diluted EPS in the last 12-months stands at $-2.658 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rexahn Pharmaceuticals, Inc’s profitability.

Rexahn Pharmaceuticals, Inc stock is trading at a EV to sales ratio of 0.0065 and a EV to EBITDA ratio of 0.0211. Its price to sales ratio in the trailing 12-months stood at 7.0794.

Rexahn Pharmaceuticals, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Rexahn Pharmaceuticals, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Rexahn Pharmaceuticals, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Rexahn Pharmaceuticals, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Rexahn Pharmaceuticals, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Rexahn Pharmaceuticals, Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$0
52-Week High
$4.26
52-Week Low
$1.2626
Analyst Target Price
$3

Rexahn Pharmaceuticals, Inc stock is currently trading at $0 per share. It touched a 52-week high of $4.26 and a 52-week low of $4.26. Analysts tracking the stock have a 12-month average target price of $3.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 0.08 indicating a short percent outstanding of 0%.

Around 30.6% of the company’s stock are held by insiders while 1146.9% are held by institutions.

Frequently Asked Questions About Rexahn Pharmaceuticals, Inc

The stock symbol (also called stock or share ticker) of Rexahn Pharmaceuticals, Inc is REXN

The IPO of Rexahn Pharmaceuticals, Inc took place on 2005-05-23

Similar Industry Stocks ()

Last Price
Chg
Chg%
Evogene (EVGN)
$0.7
-0.03
-4%
$0.22
-0.01
-2.35%
Avangrid Inc (AGR)
$40.69
0.08
+0.2%
$40.77
-1.91
-4.48%
Curis Inc (CRIS)
$0.86
0.02
+1.97%
$74.77
-3.1
-3.98%
$17.7
-0.52
-2.85%
Biophytis (BPTS)
$0.59
-0.01
-1.45%
$26.33
-4.76
-15.31%
$2.12
-0.11
-4.93%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
$0.02
0.01
+100%
Oi S.A (OIBR-C)
$0
0
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.

Address

15245 Shady Grove Road, Rockville, MD, United States, 20850